News

Jim Cramer on Vertex (VRTX): “Vertex’s Painkiller Could Be Revolutionary”
We recently published a list of 21 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Vertex ...
StockStory.org on MSN1d
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company ...
Vertex: Improved Outlook Despite First Quarter Miss (Rating Upgrade)
Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...
How To Trade VRTX Stock Ahead of Its Q1?
VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...
Fierce Biotech7h
Vertex pauses Moderna-partnered cystic fibrosis trial, takes $379M hit tied to separate program
Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...
Rising Costs Weigh on Vertex Q1 Earnings
One positive sign was that Vertex raised the lower end of its forecast for full-year 2025 revenue by $100 million. The ...
Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance
Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.